Majesco Entertainment (COOL)

[Steponit]

$COOL is doing great. Yeah, I'd welcome somebody fixing up this board. It is now PolarityTE and has nothing to do with Majesco Entertainment now. Go to the PolarityTE website if you want to read about the company. They're doing amazing stuff. Long term hold for me.

[Country Squire]

Morning, looks like a forth of the float is Short ??? Seeking Alpha tried to do a job on them, looks like there loosing, could cause the shorts to have sleepless nights, Also this web. needs updating or a new one .GLTA

[Steponit]

$25.36! Up about 32% in 7 days.

[Steponit]

Sales force expanding:

"PolarityTE(TM) Accelerates Sales Team for Targeted Regional Release of SkinTE(TM)

May 09, 2018 08:30:00 (ET)

PolarityTE(TM) Accelerates Sales Team for Targeted Regional Release of SkinTE(TM)

SALT LAKE CITY, May 09, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) announced today that it is growing its commercial presence by hiring dedicated sales representatives on the East Coast to accelerate the regional market release of SkinTE(TM). SkinTE is a human cellular and tissue-based product derived from a patient's own skin, and is intended for the repair, reconstruction, and replacement of skin tissue. SkinTE results have shown the regeneration of full-thickness (epidermis, dermis and hypodermis), functionally-polarized skin with all the appendages including hair and glands.

These dedicated sales representatives have extensive prior experience with major wound care companies and products, including product launches, and they will build on efforts to reach leaders in the field of plastic and reconstructive surgery as early adopters of SkinTE. Their regions span the Mid-Atlantic and the tri-state area of New York, New Jersey, and Pennsylvania.

"We look forward to continued growth in the adoption of SkinTE with our targeted sales strategy. Our market access and physician-lead clinical operations teams will continue to be integral to our deployment approach and will work in concurrence with the new team members to ensure providers have the necessary information and support during their initial uses of SkinTE," commented Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE. He continued, "SkinTE was designed to be simple for providers to use and we believe it is a clear improved alternative to the current available therapies for skin defects. Our early clinical outcomes from the use of SkinTE continue to ignite provider-driven demand for a product poised to change the paradigm of regenerative medicine."

About PolarityTE(TM)

PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.

About SkinTE(TM)

SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products.

SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE use is contraindicated in patients who have suffered autoimmune responses to the auto-transplantation of their own tissues.

SkinTE is regulated by the FDA as an HCT/P solely under Section 361 of the Public Health Service Act and 21 CFR 1271. The FDA has specific regulations governing HCT/Ps. HCT/Ps that meet the criteria for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271 (361 HCT/Ps) are not subject to pre-market clearance or approval requirements, but are subject to post-market regulatory requirements.

Forward Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the Company's ongoing compliance with the requirements of The NASDAQ Stock Market and the Company's ability to maintain the closing bid price requirements of The NASDAQ Stock Market on a post reverse split basis. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

CONTACT

Investors:

John Stetson

[e-mail]

[phone]

Hans Vitzthum

LifeSci Advisors, LLC

[e-mail]

[phone]

Media:

David Schull

Russo Partners LLC

[e-mail]

[phone]

Jenna Mathis

[e-mail]

[phone]

Sales:

[e-mail]

(END) Dow Jones Newswires

May 09, 2018 08:30 ET (12:30 GMT)"

[Steponit]

$24! $COOL is starting to get exciting.

[Steponit]

The success with bone regeneration sure has been received well by stockholders. I wonder if bone regeneration is an even bigger business than skin regeneration? They're both huge probably.

Looks like the long wait was worth it, and we're moving in the green direction again.

Here's a link to an article on their bone regeneration success:

https://www.polarityte.com/news-media/press-releases/detail/427/polarityte-regenerates-complex

[Steponit]

$COOL is finally starting to sprout its wings. First successful skin regeneration in humans, now successful bone regeneration in animals. And some stock analysts are finally starting to take notice.

[Steponit]

This iHub page needs to be updated. This is a regenerative skin company in the human testing stage. It has nothing to do with entertainment now. This was a shell that was transformed into stock for Polarity TE. They have numerous actual human patients now in clinical trials all over the country.

[Steponit]

Here's a link for a presentation on their SkinTE:

https://www.polarityte.com/products/skinte

[jdlamont]

as long as you have some verified personal knowledge, otherwise they need a little bit better communications to relieve shareholders this is not a scam.
seeking alpha has some good articles but it can also be a rag for shorters.

I have seen cantor put price targets on stocks that have fallen 60 to 80 per cent after their buy recommendations.

Still holding but chart looks terrible. Management needs something to break the pattern.

[Steponit]

I added some more in the low 17s this morning. Didn't think it would ever get that low again. Seems to be heading North again, back into the 18s.

Big demand from plastic surgeons all over the country during the clinical human trials. This should have a bunch of revenue pouring in as it gains acceptance. I'm holding. I'm expecting to see revenues growing at an exponential rate as this becomes the dominant medical technology in this field.

[jdlamont]

cantor has 70 dollar price target and outperform rating?
you would think it would be a fist pounding table strong buy.

[Steponit]

This presentation is great if you haven't seen it yet:

https://ir.polarityte.com

No clue why this is dropping today, but I bought some more.

[Steponit]

COOL moving up today. Probably institutional money is starting to flow in.

[Steponit]

Dipped again, and I bought some more. This will be $70 in one year according to one analyst.

[Steponit]

Great PR just came out:

PolarityTE(TM) Provides Business Updates on Clinical Use of SkinTE(TM): Regeneration of Full-Thickness Skin

Feb 05, 2018 09:00:00 (ET)

PolarityTE(TM) Provides Business Updates on Clinical Use of SkinTE(TM): Regeneration of Full-Thickness Skin

SALT LAKE CITY, Feb. 05, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (NASDAQ:COOL), today announced that initial results from the clinical applications of the commercially launched SkinTE are yielding outcomes that are correlative with the Company's preclinical research (as highlighted in the Company's recently filed Annual Report on Form 10-K), which resulted in regenerative healing of full-thickness hair-bearing skin, including all layers (epidermis, dermis, and hypodermis) and glands. The first group of patients treated with SkinTE are currently at an interim stage of healing and regeneration, and as previously announced, the Company expects final results from the initial clinical applications of SkinTE to be available in the first half of 2018, with peer-reviewed publications to follow.

SkinTE has now been used at multiple medical facilities across the country to treat the entire spectrum of wounds, including: chronic wounds, surgical wounds, reconstructive wounds, acute burns, and the replacement of scarred and contracted skin grafts with SkinTE. The initial scale-up of manufacturing operations is nearly complete, facilitating capacity to respond to ongoing demand. The Company also expects to release additional preclinical data from its OsteoTE(TM) bone regeneration development program in the first quarter of 2018.

"I have used SkinTE to partially resurface extensive burn scars and skin graft contractures in an adolescent patient. Although early in the post-operative period, the product has quickly regenerated skin with minimal marginal wound contracture and areas of regenerated skin are re-pigmenting rapidly," said Gerhard S. Mundinger, MD, Director of Plastic Surgery at Children's Hospital in New Orleans, Assistant Clinical Professor of Plastic Surgery, and Assistant Professor of Cell Biology and Anatomy at LSU Health New Orleans. "The parents, who have already been through so much in caring for their child after a terrible accident, are pleased with the results at this point. In our ongoing discussion about optimizing their child's functional recovery, we plan to use the product again in the near future to resurface more remaining scarred skin and contracted skin grafts. I am continuing to follow the patient's recovery closely, and do not have any concerns with the product at this time, although, again, it remains early in the recovery period." Dr. Mundinger continues, "I look forward to the advent of Polarity's bone regeneration product [OsteoTE] given my main clinical practice and research focus as a craniofacial surgeon."

Upon review of initial SkinTE results in humans, C. Scott Hultman, MD, MBA, FACS, the Ethel and James Valone Distinguished Chair of Plastic Surgery, Chief Emeritus and Professor, UNC Division of Plastic Surgery, said, "Having reviewed some of the preliminary in-human clinical results, I am impressed with the degree to which the melanocytes have repopulated the wound, restoring pigment where it was once absent. Furthermore, there appears to be dynamic healing: the texture and biomechanics of the grafted areas appear to change over time, during the early phases of wound healing, for the better. I am very excited to see the long-term clinical results, when available. Polarity's SkinTE may be the first real option we have for truly bioengineered skin replacement."

Denver Lough MD, PhD CEO and Chairman of PolarityTE, said, "We at PolarityTE are incredibly excited to see how SkinTE, the first product from our core tissue "TE" technology platform, is beginning to impact the lives of patients through the regeneration of their own complete skin. For those who have suffered from wounds, injuries, scars and burns as well as undergone medical reconstruction events, SkinTE is now being applied across adults and children as an entirely new paradigm of real and tangible regenerative medicine. Our mission is steadfast, and we are committed to delivering on our promise to bring incredible regenerative biomaterial technology platforms to patients and providers in a simple and pragmatic manner. With the growing success of our SkinTE product as we begin our national rollout, we look forward to sharing clinical patient images in upcoming events, as well as releasing our OsteoTE(TM) bone regeneration preclinical data."

About PolarityTE(TM)

PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. We believe that our PolarityTE platform technology is a new approach to pragmatic and functional tissue regeneration that has the potential to address many of the challenges currently facing the regenerative medicine and cell therapy markets. Recognizing the natural complexity of human tissue, our core "TE" platform begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, we create an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, we manufacture with the patient's own tissue and use the patient's own body to support the regenerative process to create the same tissue from which it was derived. We believe that our innovative method promotes and accelerates growth of the patient's tissues to undergo a form of effective regenerative healing. This revolutionary technology, paired with the Company's world-renowned clinical advisory board, position PolarityTE(TM) to drastically change the field and future of translational regenerative medicine. More information can be found online at www.PolarityTE.com.

About SkinTE(TM)

SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products.

SkinTE is regulated by the FDA as an HCT/P solely under Section 361 of the Public Health Service Act and 21 CFR 1271. The FDA has specific regulations governing HCT/Ps. HCT/Ps that meet the criteria for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271 (361 HCT/Ps) are not subject to pre-market clearance or approval requirements, but are subject to post-market regulatory requirements.

SkinTE is processed and marketed in accordance with the FDA's requirements for human tissue and current good tissue practices (21 CFR 1271) and is manufactured by American Association of Tissue Banks (AATB)- and Foundation for the Accreditation of Cellular Therapy (FACT)-accredited facilities.

Forward Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the Company's ongoing compliance with the requirements of The NASDAQ Stock Market and the Company's ability to maintain the closing bid price requirements of The NASDAQ Stock Market on a post reverse split basis. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should'" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

CONTACT

John Stetson

[e-mail]

[phone]

Investors:

Hans Vitzthum

LifeSci Advisors, LLC

[phone]

[e-mail]

(END) Dow Jones Newswires

February 05, 2018 09:00 ET (14:00 GMT)

[Steponit]

Bought some more on this dip. Impatient people sell. People buying their shares cheap win. IMO.

[Steponit]

Tests on multiple human patients with multiple types of wounds. This is getting exciting. I'm holding at least until the first results get published. And if those go well, this should skyrocket. And I'm glad I was able to add a bunch more during that big quick dip yesterday.

[Steponit]

Looks like a major short attack today. Good time to load up. I just did.

[Steponit]

I don't know about you guys, but I'm buying on these dips.

[Ubertino]

When it looks like a duck, quaks like a duck and walks like a duck, it's a scam.

[Ex Blockman]

COOL ~ How cool is COOL. After hearing for months from my fan club that COOL is a POS, she's risen from $3.16 to as high as $30.09. The correction, documented in my previous charts, has been called to the point, with the exception of the recent pullback to $18.00. I was hoping and looking for $16.00. Those that re-entered just outside the lower bollie in the $18s are already up another nice chunk. Since the stock is beginning to breech the upper bollie and approaching a previous to in the high $20s/low $30s, stay on top of this swing trade. We'll probably begin peeling a few off again as the indicators are getting a bit overbought.

[Ex Blockman]

COOL ~ A great move from $3.16 up to as high as $30.09, which also included three nice swings along the way. After breaking under the MA20 and MA50, the next target would be the previous low of $16.00 set in mid-June. Let's see what develops.

[Ex Blockman]

COOL..... MA20 test a success. Perfect correction from $30.09 to the bounce off the MA20. Indicators still up there, but another great entry and swing.

[Ex Blockman]

COOL - First test of the MA20 this morning. Still waiting for the FullSto and MACDs to reset. Still too overbought. Good news is, COOL is down over $8.00 when I mentioned it was too overbought 1.5 weeks ago.

[Ex Blockman]

COOL ~ $6.00 down from Monday's trap and gap..... Hopefully heading to the MA20 for yet another re-entry. Been a great on to swing trade. Looking great!

[Ex Blockman]

*COOL* correction underway as I believed was coming. Down approx $5.00 from yesterdays gap and trap formation. Now the question remains, how far and how long.

[Ex Blockman]

I for one, don't care. Sold the rest of my shares just now on the opening. From $3.21 to as high as $30.00. Waiting for a technical correction now as the chart/technicals are overbought.

See you again after a pullback.

[christalball]

Is Polarityte gonna start making money again?

[christalball]

This POS is nuts.
I am insanely jealous.
Had cool for years and sold at 3
before it went south.
Lost track of it till it was too late.
FINS are terrible.
Don't quite get it.

[Ex Blockman]

COOL ~ How cool is COOL!....... Awesome call since late Dec/early Jan. I made a mistake in buying the stock back then and not going onto margin in the $5.00+ level. On its way to $100 over time.

[oldfart9]

I bought a few shares at about $11, but I have no idea what is causing this latest surge.

[ddbl_our_buck]

..followed this since $12 ~ ugh..
Glta

[oldfart9]

What is going on with this stock? It's been going crazy the last couple of days.

[bigee]

That's because they bought the company from majesco. Company change

[236T568]

COOL - $110 million Net Loss for the quarter ending April 30, 2017




http://ih.advfn.com/p.php?pid=nmona&article=74972274

[bigee]

It's moving again up

[ddbl_our_buck]

Wow thanks..

[ddbl_our_buck]

Hi board. I follow ONV* long term. They grow human tissue; liver and kidney. This stock looks similar and interesting also. May set the table
Good day

[bigee]

Nice

[236T568]

Patent in regeneration of skin cells issued for competing process/product to that of COOL's patent application



http://www.masslive.com/news/worcester/index.ssf/2016/05/wpi_researchers_get_a_patent_t.html

[Marketwise]

After reading a little of Ms. Buhl's journalism on these people I have decided to play this thing short. Thank you Ms. Buhl for the courageous reporting. Absolutely report things as you actually and truthfully see them after thoroughly and unbiasedly investigating them...:)

[Jess070283]

Squeeze em!

[236T568]

COOL hits $17.37 - $299 million Market Cap (fully diluted)

[236T568]

COOL market cap = $231 million

using 17.2 million common shares outstanding (fully diluted)

[236T568]

COOL COMMON SHARES OUTSTANDING = 17.2 MILLION (fully diluted)



https://www.sec.gov/Archives/edgar/data/1076682/000149315217002349/ex99-1.htm

[Jess070283]

Let's bust these HOD's!!

[Jess070283]

$15++++ EOD

[bigee]

Why the pop 11.04

[stock_miscreant]

Why the drop?@